Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 44.4 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human Osteoprotegerin, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) at 10 μg/mL (100 μL/well) can bind Human Osteoprotegerin, His Tag (Cat. No. TNB-H5220) with a linear range of 5-156 ng/mL (QC tested).
Immobilized Human Osteoprotegerin, His Tag (Cat. No. TNB-H5220) at 5 μg/mL (100 μL/well) can bind Human TRAIL, Mouse IgG2a Fc Tag with a linear range of 0.5-16 ng/mL (Routinely tested).
Loaded Human Osteoprotegerin, His Tag (Cat. No. TNB-H5220) on HIS1K Biosensor, can bind Human TRAIL with an affinity constant of 0.831 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Narlumosbart | JMT-103 | Approved | Shanghai Jmt-Bio Inc | 津立泰, 津立生 | Mainland China | Giant Cell Tumor of Bone | Shanghai Jmt-Bio Inc | 2023-09-05 | Bone metastases; Solid tumours; Osteoporosis; Hypercalcemia; Bone Diseases; Neoplasms; Osteoporosis, Postmenopausal; Multiple Myeloma; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis | Details |
Denosumab biosimilar (Mabwell) | 9-MW-0311; 9MW0321; 9-MW0321; 9MW-0321; 9-MW-0321; TK-006; MW-032; MW-031; 9MW0311; 9-MW0311; 9MW-0311 | Approved | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 迈利舒, 迈卫健, MAIWEIJIAN, MAILISHU | Mainland China | Osteoporosis, Postmenopausal | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 2023-03-28 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Breast Neoplasms; Bone Neoplasms; Giant Cell Tumor of Bone | Details |
Denosumab biosimilar (Qilu Pharma) | QL-1206 | Approved | Qilu Pharmaceutical Co Ltd | 鲁可欣 | Mainland China | Osteoporosis, Postmenopausal | Qilu Pharmaceutical Co Ltd | 2023-09-28 | Bone metastases; Solid tumours; Osteoporosis, Postmenopausal; Giant Cell Tumor of Bone | Details |
Denosumab biosimilar (Boan Biopharma/Luye) | LY-01011; BA-1102; BA-6101; LY-06006 | Approved | Shandong Boan Biotechnology Co Ltd | 博洛加, Boluojia, Boyoubei | Mainland China | Osteoporosis, Postmenopausal | Shandong Boan Biotechnology Co Ltd | 2022-11-10 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Neoplasms; Giant Cell Tumor of Bone; Bone Neoplasms; Neoplasm Metastasis | Details |
Denosumab | NSC-744010; AMG-162 | Approved | Amgen Inc | Prolia, Xgeva, Pralia, Ranmark, 普罗力 | EU | Osteoporosis, Postmenopausal | Amgen Europe Bv | 2010-05-26 | Lymphoma, Non-Hodgkin; Bone Cysts, Aneurysmal; Feeding and Eating Disorders; Breast Neoplasms; Giant Cell Tumors; Prostatic Neoplasms; Osteogenesis Imperfecta; Osteosarcoma; Arthropathy, Neurogenic; Giant Cell Tumor of Bone; Bone Neoplasms; Breast Diseases; Thyroid Neoplasms; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Fractures, Bone; Carcinoma, Squamous Cell; Osteoblastoma; Granuloma, Giant Cell; Glucocorticoid-induced osteoporosis; Lymphoma; Metastatic breast cancer; Neoplasm Metastasis; Anorexia Nervosa; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Fibroma; Renal Insufficiency; Solid tumours; Bone metastases; Endocrine Gland Neoplasms; Cataract; Kidney Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Parathyroid Neoplasms; Osteoporosis; Bone Diseases, Metabolic; Carcinoma; Pain; Fibrous Dysplasia of Bone; Head and Neck Neoplasms; Hypercalcemia; Arthritis, Rheumatoid; Osteoporosis, Postmenopausal; Colonic Neoplasms; Hodgkin Disease; Neoplasms; Smoldering Mu | Details |
Denosumab biosimilar(Reliance Life Sciences) | R-TPR-045 | Approved | Reliance Life Sciences | DenosuRel | India | Osteoporosis, Postmenopausal; Bone metastases | Reliance Life Sciences | 2022-02-01 | Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Sandoz) | GP-2411 | Approved | Novartis Pharma Ag, Sandoz | Jubbonti®, Wyost® | United States | Osteoporosis, Postmenopausal; Osteoporosis; Glucocorticoid-induced osteoporosis | Sandoz, Sandoz Inc | 2024-03-05 | Osteoporosis; Osteoporosis, Postmenopausal; Bone Resorption; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis | Details |
Denosumab biosimilar (Alphamab) | KN-012 | Approved | Suzhou Alphamab Co Ltd | Mainland China | Osteoporosis, Postmenopausal | Philippine Biological Technology (Jilin) Co Ltd, Alphamab Jilin Co Ltd | 2024-09-03 | Osteoporosis, Postmenopausal | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Denosumab biosimilar (Intas Biopharmaceuticals) | Phase 3 Clinical | Intas Biopharmaceuticals | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar(Shanghai Hansoh) | HS-20090; HS-20090-2 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours; Bone metastases; Bone Diseases; Hypercalcemia; Osteoporosis, Postmenopausal; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Nutritional and Metabolic Diseases | Details |
Denosumab biosimilar (Teva Pharmaceutical) | TVB-009; TVB-009P | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Osteoporosis, Postmenopausal | Details |
CMAB807 | CMAB-807; CMAB807X | Phase 3 Clinical | Shanghai Biomabs Pharmaceuticals Co Ltd, Shanghai Maitai Yabo Biotechnology Co Ltd | Osteoporosis, Postmenopausal | Details |
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms; Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (GlycoNex) | SPD8; SPD-8 | Phase 3 Clinical | Glyconex Inc | Osteoporosis; Neoplasms | Details |
Denosumab biosimilar (Hetero Biopharma) | Phase 3 Clinical | Hetero Biopharma Ltd | Solid tumours | Details | |
Denosumab biosimilar(Curateq Biologics) | BP-16 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Enzene Biosciences) | ENZ-215 | Phase 3 Clinical | Enzene Biosciences Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Alvotech Swiss) | AVT03; AVT-03 | Phase 3 Clinical | Alvotech Swiss Ag | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Mabxience) | Phase 3 Clinical | Mabxience Sa | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (Hualan Biological Engineering) | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (Gedeon Richter) | RGB-14-P | Phase 3 Clinical | Gedeon Richter Plc | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Fresenius Kabi) | FKS-518 | Phase 3 Clinical | Fresenius Kabi Swissbiosim Gmbh | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Samsung Bioepis) | SB-16 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Osteoporosis, Postmenopausal | Details |
Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke) | Phase 3 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimiliar (Celltrion) | CT-P41 | Phase 3 Clinical | Celltrion Inc | Osteoporosis, Postmenopausal | Details |
LZM-004 | LZM-004 | Phase 1 Clinical | Livzon(Group) Pharmaceutical Factory | Bone metastases | Details |
Recombinant human anti-RANKL antibody (Innovent Biologics) | IBI-307 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Osteoporosis | Details |
GB-223 | GB-223; GB223 | Phase 1 Clinical | Genor Biopharma Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Bone Neoplasms; Giant Cell Tumor of Bone | Details |
Recombinant human anti-RANKL antibody (Hisun Pharma) | HS629 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours; Bone metastases | Details |
This web search service is supported by Google Inc.